Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Assess the pros and cons of emergency versus sinking funds to determine which is more suitable for your goals, and how to combine them effectively.
23,964 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
As Alabama lawmakers move toward compromise on utility bills, investors argue that southern company risk looks more m...
Geopolitical tensions push fuel costs higher, prompting DoorDash to fund more than $50 million in gas-price relief fo...
In a volatile world, a few dominant companies offer steadier upside. This article spotlights two stocks with monster ...
After an 11% drop, investors wonder if CoreWeave stock can rebound. This article weighs the bull and bear cases, what...
This deep-dive breaks down veru (veru) 2026 earnings, translating the quarterly numbers into a clear sense of cash he...
When micron stock just dropped, it sparked questions about the memory market and Micron's long-term roadmap. This gui...
A strategic shift in how the government engages with industry is triggering a market rethink. The administration is t...
Truth Social’s spot Bitcoin ETF has withdrawn its S-1 filing, signaling tougher market conditions for plain-vanilla c...
A leaked Meta audio from an April 30 all-hands meeting signals a shift toward leveraging compute and internal output ...
Shares surged after quarterly results, lifting the outlook for this dividend-paying chip stock. Analysts say the stoc...
The bitcoin’s drop toward $72,000 intensified as U.S.-Iran tensions resurfaced, prompting a risk-off move across cryp...